Moderna touts first look at mRNA protein replacement for rare metabolic disease

LOS ANGELES — Moderna presented early data on its mRNA treatment for propionic acidemia (PA), a rare metabolic disease where people can’t break down certain proteins and fats, suggesting patients had fewer severe attacks characteristic of the disease following treatment. It’s the first time Moderna has shared clinical results of…